Advertisement

Header Utility Menu

  • Subscribe
  • Advertise
  • Contact Us
  • Events

LinkedIn Facebook Twitter Instagram Get Our App

  • Login

Virginia Business

Mobile Menu

  • Issues
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Advertisement

Header Primary Menu

  • Issues
    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • Issues Archive
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Home News U.Va. research to inform COVID-19 drug treatment

U.Va. research to inform COVID-19 drug treatment

A 2019 U.Va. study will inform testing of antidepressant as a treatment for virus

Published May 13, 2020 by Sydney Lake

The University of Virginia School of Medicine announced Tuesday that results from a 2019 U.Va. study are being used to inform a national study looking into the effectiveness of the antidepressant medication fluvoxamine as a potential treatment for COVID-19. Researchers at Washington University School of Medicine in St. Louis say the drug may prevent dangerous overreactions by the immune system.

“I am excited to see the results from this clinical trial,” U.Va. researcher Alban Gaultier said in a statement. “If proven effective in decreasing the symptoms of COVID-19, this treatment would be a safe and affordable option for fighting the pandemic.”

Last year, U.Va. researchers Gaultier and Dorian A Rosen studied the use of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) typically used to treat obsessive compulsive disorder, for stopping sepsis. Sepsis is a deadly inflammation that occurs when chemicals are released in the bloodstream to fight an infection. 

In their study, Gaultier and Rosen determined that fluvoxamine reduced the production of cytokines — proteins produced by cells. If too many cytokines flood the body at once, it can lead to life-threatening organ failure. The U.Va. researchers’ experiments on mice were effective in treating sepsis, and now will be tested at Washington University for the same effect in treating patients with COVID-19.

According to Washington University researcher Dr. Caline Mattar, COVID-19 appears to have two key phases: the first caused by the viral infection and the second by the body’s inflammatory response. “The first is caused by the viral infection itself, which gives people a fever and a cough and makes them feel ill, among other symptoms,” Mattar said in a statement. “The information we have so far suggests that the second phase of the illness can involve a life-threatening inflammatory reaction — what we call a ‘cytokine storm.’ We want to learn whether fluvoxamine might help prevent that second phase of the illness.”

Dr. Eric J. Lenze at Washington University plans to test fluvoxamine in 152 patients with COVID-19 in Illinois and Missouri. While quarantined at home, patients will receive fluvoxamine or a placebo treatment. To report oxygen levels and vital signs, the patients will receive thermometers, fingertip oxygen sensors and automatic blood pressure monitors. 

“Using a psychiatric drug to treat COVID-19 may sound counterintuitive, but it’s no more counterintuitive than using a malaria drug,” Lenze said in a statement. “This drug has been around for decades, so we know how to use it safely. If effective, it could be an ideal drug to repurpose for outpatients with COVID.”

 

Subscribe to Virginia Business.

Get our daily e-newsletter.

Related Stories

Virginia Business logo

U.Va. staff member tests positive for COVID-19

Employee works for U.Va. Women's Center

Va. ER physician spearheads intubation PPE production

Boxes protecting physicians during intubation will be distributed statewide.

Virginia Business logo

Virginia Tech develops in-house COVID-19 testing

Results can be returned to area health departments as soon as the same day.

Trending

13th annual Best Places to Work

Making strides

It’s back!

After the crisis

Fort Monroe development moving forward

Sponsored Stories

Working at Pinnacle Financial Partners

What Logistics issues will have the biggest impact on you in 2023?

In the New Year, Aim for Better Cybersecurity

4 innovative ways to create capacity

WHERE IS THE SUPPLY CHAIN WHEN YOU NEED IT?

P.A.I.N.T. Your Financial Mountain

5 Benefits of Treasury Management Services from Atlantic Union Bank

Blazing trails in the digital landscape

Advertisement

Advertisement

Trending

13th annual Best Places to Work

Making strides

It’s back!

After the crisis

Fort Monroe development moving forward

Sponsored Stories

Working at Pinnacle Financial Partners

What Logistics issues will have the biggest impact on you in 2023?

In the New Year, Aim for Better Cybersecurity

4 innovative ways to create capacity

WHERE IS THE SUPPLY CHAIN WHEN YOU NEED IT?

P.A.I.N.T. Your Financial Mountain

5 Benefits of Treasury Management Services from Atlantic Union Bank

Blazing trails in the digital landscape

Get Virginia Business directly on your tablet or in your mailbox!

Subscribe to Virginia Business

Advertisement

Advertisement

Footer Primary Menu

  • virginiabusiness.com
  • Subscribe
  • Advertise
  • About Us
  • Contact Us

Footer Secondary Menu

  • Industries
  • Regions
  • Reports
  • Company News
  • Events

Sign Up For Our Newsletter

Sign Up

LinkedIn Facebook Twitter Instagram Get Our App

Privacy Policy Cookie Policy

Footer Utility Menu

Copyright © 2023 Virginia Business. All rights reserved.

Site Maintained by TechArk